Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Variants/Fusion

Fusion

CIViC ID: 1 · Gene: BCR::ABL1

Variant Summary

Also known as: T(9;22)(Q34;Q11),BCR-ABL1,BCR-ABL
HGVS: —
Variant Type(s): transcript_fusion
Evidence Items: 19

Evidence Level Distribution

Level A: 5Level B: 9Level C: 3Level D: 2

Evidence Items

Showing CIViC evidence rows where gene = BCR::ABL1 and variant = Fusion.

Level	Type	Direction	Significance	Disease	Drugs	Rating
A	Predictive	Supports	Sensitivity/Response	Acute Myeloid Leukemia	Imatinib	5
A	Predictive	Supports	Sensitivity/Response	Chronic Myeloid Leukemia	Imatinib	5
A	Predictive	Supports	Sensitivity/Response	Chronic Myeloid Leukemia	Imatinib	5
B	Diagnostic	Supports	Positive	Acute Myeloid Leukemia With BCR-ABL1		4
B	Diagnostic	Supports	Positive	Acute Myeloid Leukemia With BCR-ABL1		4
B	Diagnostic	Supports	Positive	Acute Myeloid Leukemia With BCR-ABL1		4
B	Diagnostic	Supports	Positive	B-lymphoblastic Leukemia/lymphoma With BCR-ABL1		4
B	Diagnostic	Supports	Positive	B-lymphoblastic Leukemia/lymphoma With BCR-ABL1		4
B	Diagnostic	Supports	Positive	B-lymphoblastic Leukemia/lymphoma With BCR-ABL1		4
B	Diagnostic	Supports	Positive	Chronic Myeloid Leukemia		4
B	Diagnostic	Supports	Positive	Chronic Myeloid Leukemia		4
A	Diagnostic	Supports	Positive	Chronic Myeloid Leukemia		4
A	Predictive	Supports	Sensitivity/Response	Chronic Myeloid Leukemia	Dasatinib,Nilotinib	4
C	Predictive	Supports	Sensitivity/Response	Chronic Myeloid Leukemia	Dasatinib	4
B	Diagnostic	Supports	Positive	B-lymphoblastic Leukemia/lymphoma With BCR-ABL1		3
D	Predictive	Supports	Resistance	Acute Myeloid Leukemia	Imatinib	3
C	Predictive	Supports	Sensitivity/Response	Acute Lymphoblastic Leukemia	Dasatinib	3
D	Predictive	Supports	Sensitivity/Response	Chronic Myeloid Leukemia	Nilotinib,Bafetinib,Dasatinib	3
C	Diagnostic	Does Not Support	Positive	Chronic Myeloid Leukemia		2